MCAS Diagnosis: Criteria, Testing, and Why This Condition Gets Missed

The Three Diagnostic Criteria

Regardless of which diagnostic framework a clinician uses, MCAS diagnosis rests on three pillars. All three must be met for a formal diagnosis [1].

Criterion 1: Episodic Symptoms in Two or More Organ Systems

MCAS is a systemic condition. Mast cells are present in virtually every tissue in the body, which is why symptoms can be so diverse and seemingly unrelated. For diagnosis, a patient must demonstrate recurrent or chronic symptoms that involve at least two organ systems [2].

Common symptom patterns by organ system include:

• Skin: Flushing, hives (urticaria), itching, angioedema (swelling), dermatographia
• Gastrointestinal: Abdominal pain, nausea, diarrhea, bloating, cramping, reflux
• Cardiovascular: Tachycardia, hypotension, lightheadedness, presyncope or syncope
• Respiratory: Wheezing, shortness of breath, nasal congestion, throat tightness
• Neurological: Brain fog, headache, dizziness, difficulty concentrating
• Musculoskeletal: Joint pain, muscle pain, generalized aching
• Constitutional: Fatigue, malaise, temperature dysregulation

A hallmark of MCAS is that these symptoms tend to be episodic and fluctuating rather than constant, often occurring in “flares” triggered by identifiable (or sometimes mysterious) stimuli. Patients frequently describe good days and terrible days with no obvious pattern, at least until triggers are identified [3].

Criterion 2: Laboratory Evidence of Mast Cell Mediator Elevation

This is the criterion that gives clinicians and patients the most trouble. Mast cells release a wide range of mediators, and testing must capture at least one of them at elevated levels during or near a symptomatic episode.

The most commonly tested mediators include:

• Serum tryptase: The most widely available test. A rise of 20% above baseline plus 2 ng/mL is considered significant per consensus criteria. Note: baseline tryptase in MCAS is often normal, which is a key distinction from systemic mastocytosis where baseline tryptase is typically elevated above 20 ng/mL [4]
• 24-hour urine N-methylhistamine: The primary urinary metabolite of histamine. More reliable than serum histamine because it captures total histamine production over 24 hours rather than a single point in time [5]
• 24-hour urine prostaglandin D2 (or its metabolite 11-beta-prostaglandin F2-alpha): Prostaglandin D2 is relatively specific to mast cells and can be elevated even when histamine and tryptase are normal [6]
• Plasma histamine: Can be tested but is technically challenging because histamine has an extremely short half-life in blood (about 1 minute). The sample must be processed and frozen very quickly
• Serum chromogranin A: Sometimes elevated in MCAS but is nonspecific and can be raised by proton pump inhibitors and other conditions
• Heparin: Mast cells release heparin during degranulation, and plasma heparin levels can be tested, though this is not widely available

Criterion 3: Response to Mast Cell-Targeted Therapy

The third criterion is clinical: symptoms must improve with medications that block mast cell mediators or stabilize mast cells. This includes antihistamines (H1 and H2 blockers), mast cell stabilizers (cromolyn sodium, ketotifen), leukotriene inhibitors, or other mast cell-targeted interventions [1].

This criterion serves as a therapeutic confirmation. If a patient has multisystem symptoms, some evidence of mediator elevation, and then responds to antihistamine therapy, the pattern is consistent with mast cell-driven disease. If targeted therapy produces no improvement at all, alternative diagnoses should be reconsidered.

Timing Labs During Flares

Here is the single most practical piece of advice for MCAS testing: draw labs during or as close to a symptomatic flare as possible.

Mast cell mediators are released episodically. Between flares, levels may return to normal. Drawing tryptase on a good day when a patient feels relatively well will often produce a normal result, even in someone with clinically significant MCAS. This leads to the frustrating pattern of “your labs are normal” that many MCAS patients experience repeatedly before diagnosis [7].

Practical strategies for flare-timed testing:

• For serum tryptase: Ideally drawn within 30 minutes to 2 hours of a flare. Tryptase peaks about 60 to 90 minutes after mast cell degranulation and returns to baseline within several hours [4]
• For plasma histamine: Must be drawn during active symptoms and processed immediately. Histamine’s half-life in blood is approximately 1 minute, so delays between draw and processing will produce falsely normal results
• For 24-hour urine collections: Start the collection during a flare period. If you are having a bad symptom day, that is the day to start collecting. Some clinicians ask patients to keep collection supplies at home so they can begin a collection as soon as a significant flare occurs

A practical approach: have your clinician order the labs in advance so that standing orders are already on file at the lab. When a flare happens, you go directly to the lab without waiting for a new appointment. Some patients keep a cooler with ice packs in their car so they can drive immediately to a draw site during symptoms.

Consensus Criteria vs. Afrin Criteria

One of the ongoing controversies in MCAS diagnosis is the difference between two competing diagnostic frameworks. Understanding this distinction matters because it affects who gets diagnosed and how quickly.

The Consensus Criteria (Valent et al., 2012 / Updated 2019)

The international consensus criteria, developed by a group led by Peter Valent, require [1]:

1. Episodic symptoms consistent with mast cell mediator release affecting two or more organ systems
2. A documented increase in validated mast cell mediators (primarily serum tryptase, with the 20% + 2 ng/mL rise during a symptomatic episode compared to the patient’s baseline)
3. Response to therapy targeting mast cell mediator production or effects

The consensus criteria place heavy emphasis on the tryptase rise as the preferred laboratory marker and maintain strict requirements for mediator documentation.

The Alternative Criteria (Afrin et al., 2020)

Lawrence Afrin and colleagues published a proposed alternative framework that broadens the laboratory criterion [8]. Their approach:

1. Chronic and/or recurrent symptoms consistent with mast cell activation in two or more organ systems
2. Laboratory evidence of elevated mast cell mediators, accepting a wider range of markers including urinary histamine metabolites, prostaglandins, heparin, and chromogranin A, not just tryptase
3. Symptomatic improvement with mast cell-targeted therapy
4. Exclusion of other conditions that better explain the symptom pattern

The Afrin criteria accept more mediator tests as valid evidence and do not require the specific tryptase rise that the consensus criteria emphasize. This matters because many MCAS patients never show a tryptase rise, even during flares, while showing elevations in prostaglandins or urinary histamine metabolites instead [9].

Why This Matters Clinically

The practical consequence is that patients evaluated under the strict consensus criteria may be told they do not have MCAS (because their tryptase never budges), while the same patients evaluated under the Afrin criteria (which accept prostaglandin or urinary histamine elevation) may receive a diagnosis and treatment. Neither framework is universally accepted, and this disagreement among experts is a significant contributor to diagnostic delays and confusion [10].

Most clinicians who specialize in MCAS tend to use a pragmatic blend: they try to meet the consensus criteria when possible but do not dismiss patients whose clinical picture and broader mediator panels are consistent with mast cell activation, even if tryptase is stubbornly normal.

Differential Diagnosis: What Else Could It Be?

Because MCAS symptoms are so diverse, the differential diagnosis list is long. A thorough clinician will consider and rule out conditions that mimic MCAS before (or alongside) arriving at the diagnosis.

• Systemic mastocytosis: A distinct condition involving clonal proliferation of abnormal mast cells. Distinguished from MCAS by bone marrow biopsy showing dense mast cell infiltrates, KIT D816V mutation, and persistently elevated baseline tryptase above 20 ng/mL [11]
• Hereditary alpha-tryptasemia (HaT): A genetic condition (extra copies of the TPSAB1 gene) that causes elevated baseline tryptase and can cause MCAS-like symptoms. Identified through genetic testing [12]
• Carcinoid syndrome: A neuroendocrine tumor that produces serotonin and other mediators, causing flushing, diarrhea, and wheezing. Diagnosed through 24-hour urine 5-HIAA and imaging
• Pheochromocytoma: An adrenal tumor producing catecholamines, causing episodic hypertension, flushing, and tachycardia. Diagnosed through plasma or urine metanephrines
• Histamine intolerance: Impaired breakdown of dietary histamine, often due to DAO enzyme deficiency. Symptoms overlap significantly with MCAS but are driven by exogenous histamine rather than endogenous mast cell mediator release
• Autoimmune conditions: Lupus, vasculitis, and other autoimmune diseases can produce episodic multisystem symptoms
• Anxiety and panic disorder: Tachycardia, flushing, GI distress, and breathlessness during panic attacks can mimic MCAS flares. Some patients have both conditions concurrently

Why MCAS Is Underdiagnosed

Conservative estimates suggest that MCAS may affect up to 17% of the population in some form [3]. Yet most patients report years or even decades of symptoms before receiving a diagnosis. Several factors contribute to this gap.

Lack of Awareness in Primary Care

MCAS was not formally described as a distinct entity until the 2000s, and it has been slow to enter mainstream medical education. Many primary care physicians and even specialists have limited familiarity with the condition. Patients presenting with fluctuating multisystem symptoms are frequently diagnosed with anxiety, irritable bowel syndrome, chronic fatigue syndrome, or “medically unexplained symptoms” without mast cell activation being considered [13].

Testing Is Technically Demanding

The laboratory requirements for MCAS testing are more exacting than standard blood work. Plasma histamine requires immediate chilled processing. Tryptase must be drawn during a narrow time window around flares. Prostaglandin testing requires specific urine collection conditions. Many general labs do not handle these samples correctly, leading to degraded specimens and falsely normal results [7].

Normal Baseline Labs Create a False Sense of Reassurance

When a patient has routine blood work drawn on a stable day and everything comes back normal, clinicians may feel confident ruling out a mast cell problem. But in MCAS, mediator levels fluctuate dramatically. A normal tryptase level drawn on a Tuesday when the patient felt fine says nothing about what that level was on Saturday when they were flushing, tachycardic, and doubled over with abdominal pain.

Symptom Overlap With Common Conditions

Every individual MCAS symptom can be attributed to something else. Flushing can be menopause. GI pain can be IBS. Tachycardia can be anxiety. Hives can be “idiopathic urticaria.” Each specialist sees the piece that falls within their domain and treats it in isolation, while the unifying mechanism goes unrecognized [14].

Which Specialists Diagnose MCAS?

Several types of specialists may evaluate and diagnose MCAS, though experience with the condition varies widely within each specialty.

• Allergists/Immunologists: The most natural fit, as mast cell disease falls within their training scope. However, not all allergists are comfortable with MCAS, particularly those whose practice focuses primarily on environmental allergies and asthma
• Hematologists: Particularly those who specialize in mastocytosis. They are well-equipped to distinguish between MCAS and systemic mastocytosis and to perform bone marrow biopsies if needed
• Functional and integrative medicine practitioners: An increasing number of practitioners in this space have developed expertise in MCAS diagnosis and management, especially in the context of overlapping conditions like Ehlers-Danlos syndrome and POTS
• Gastroenterologists: May be involved when GI symptoms dominate the clinical picture, though most GI doctors will not independently arrive at an MCAS diagnosis without prompting

Finding a provider who has specific experience with MCAS is more important than the type of specialist. A general allergist who has never evaluated a patient for MCAS will be less helpful than a functional medicine physician who diagnoses it regularly. Patient advocacy organizations such as The Mast Cell Disease Society maintain provider directories that can help [15].

Building Your Case: Practical Steps

If you suspect MCAS, here are concrete steps to move toward diagnosis:

1. Document your symptoms systematically. Keep a log of episodes, noting which organ systems are involved, potential triggers, timing, and severity. Two or more months of documented multisystem episodes is compelling
2. Get standing lab orders. Ask your clinician to order serum tryptase and a 24-hour urine panel (N-methylhistamine, prostaglandin D2/11-beta-PGF2-alpha, leukotriene E4) in advance so they are on file when a flare occurs
3. Time your labs during flares. For serum tryptase, get to the lab within 30 minutes to 2 hours of significant symptoms. For urine, start the 24-hour collection on a bad symptom day
4. Request a trial of H1 + H2 antihistamines. Even before formal lab confirmation, a clinician may agree to a therapeutic trial of dual antihistamine therapy. A clear positive response supports the third diagnostic criterion
5. Seek a knowledgeable specialist. If your primary care provider is unfamiliar with MCAS, a referral to an allergist, immunologist, or hematologist with mast cell disease experience is the most direct path forward

Related Reading

• Mast Cell Activation Syndrome: Complete Guide
• MCAS Treatment: Medications, Supplements, and a Layered Approach
• Low-Histamine Diet for MCAS: What to Eat and Avoid
• Histamine Intolerance: Causes, Symptoms, and Management

References

1. Valent P, Akin C, Arock M, et al. “Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal.” Int Arch Allergy Immunol. 2012;157(3):215-225. doi:10.1159/000328760
2. Molderings GJ, Brettner S, Homann J, Afrin LB. “Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options.” J Hematol Oncol. 2011;4:10. doi:10.1186/1756-8722-4-10
3. Afrin LB, Self S, Menk J, Lazarchick J. “Characterization of Mast Cell Activation Syndrome.” Am J Med Sci. 2017;353(3):207-215. doi:10.1016/j.amjms.2016.12.013
4. Schwartz LB. “Diagnostic value of tryptase in anaphylaxis and mastocytosis.” Immunol Allergy Clin North Am. 2006;26(3):451-463. doi:10.1016/j.iac.2006.05.010
5. Keyzer JJ, de Monchy JG, van Doormaal JJ, van Voorst Vader PC. “Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites.” N Engl J Med. 1983;309(26):1603-1605. doi:10.1056/NEJM198312293092603
6. Roberts LJ 2nd, Sweetman BJ, Lewis RA, Austen KF, Oates JA. “Increased production of prostaglandin D2 in patients with systemic mastocytosis.” N Engl J Med. 1980;303(24):1400-1404. doi:10.1056/NEJM198012113032405
7. Afrin LB. “Mast cell activation disease and the modern epidemic of chronic inflammatory disease.” Transl Res. 2016;174:33-59. doi:10.1016/j.trsl.2016.01.003
8. Afrin LB, Ackerley MB, Bluestein LS, et al. “Diagnosis of mast cell activation syndrome: a global ‘consensus-2’.” Diagnosis (Berl). 2021;8(2):137-152. doi:10.1515/dx-2020-0005
9. Vysniauskaite M, Hertfelder HJ, Oldenburg J, et al. “Determination of plasma heparin level improves identification of systemic mast cell activation disease.” PLoS One. 2015;10(4):e0124912. doi:10.1371/journal.pone.0124912
10. Weiler CR, Austen KF, Akin C, et al. “AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management.” J Allergy Clin Immunol. 2019;144(4):883-896. doi:10.1016/j.jaci.2019.08.023
11. Pardanani A. “Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management.” Am J Hematol. 2021;96(4):508-525. doi:10.1002/ajh.26118
12. Lyons JJ, Yu X, Hughes JD, et al. “Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number.” Nat Genet. 2016;48(12):1564-1569. doi:10.1038/ng.3696
13. Molderings GJ, Haenisch B, Bogdanow M, de Monchy JG, Afrin LB. “Familial occurrence of systemic mast cell activation disease.” PLoS One. 2013;8(9):e76241. doi:10.1371/journal.pone.0076241
14. Hamilton MJ, Hornick JL, Akin C, Castells MC, Greenberger NJ. “Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations.” J Allergy Clin Immunol. 2011;128(1):147-152.e2. doi:10.1016/j.jaci.2011.04.037
15. The Mast Cell Disease Society. “Find a Specialist.” https://tmsforacure.org/. Accessed 2025.